Skip to main content
Thomas Yau, MD, Ophthalmology, Silver Spring, MD

ThomasYauMD

Ophthalmology • Silver Spring, MD

Cataract Related, Retinal Disease

managing partner, Silver Spring Eye

Join to view full profile

Dr. Yau is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Yau's full profile

Already have an account?

  • Office

    8630 Fenton St
    Suite 514
    Silver Spring, MD 20910
    Phone+1 301-587-1220
    Fax+1 301-587-1269

Education & Training

  • MedStar Health/Georgetown-Washington Hospital Center
    MedStar Health/Georgetown-Washington Hospital CenterResidency, Ophthalmology, 1994 - 1997
  • Mercy Medical Center
    Mercy Medical CenterInternship, Preliminary Year, 1993 - 1994
  • University of Maryland School of Medicine
    University of Maryland School of MedicineClass of 1993

Certifications & Licensure

  • DC State Medical License
    DC State Medical License 1997 - 2027
  • MD State Medical License
    MD State Medical License 1997 - 2025
  • VA State Medical License
    VA State Medical License 2002 - 2006
  • Ophthalmology
    American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • Top Doctors:Washington DC Area Castle Connolly
  • Top Doctors, Washingtonian Magazine 2008, 2010, 2012, 2014, 2016-2017
  • Top Doctors:Washington-Baltimore Castle Connolly, 2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020

Press Mentions

  • Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
    Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with SorafenibNovember 1st, 2020
  • Novel Systemic Therapy for Hepatocellular Carcinoma
    Novel Systemic Therapy for Hepatocellular CarcinomaJuly 13th, 2020
  • Patient-Reported Outcomes Show Newer Drug Combinations Maintain Quality of Life Longer Than Current Standard-of-Care Treatments
    Patient-Reported Outcomes Show Newer Drug Combinations Maintain Quality of Life Longer Than Current Standard-of-Care TreatmentsFebruary 13th, 2020
  • Join now to see all

Professional Memberships

Other Languages

  • Chinese (Cantonese)

Dr. Thomas Yau, Dr. Thomas Yau, MD, Dr. T Yau